Abstract
total dose): # doses: 3:93% vs. 4-6: 90% und 7: 77%; p 0.025, total dose: 600mg: 93%, 600-1000mg: 94%, 1000mg: 75%; p 0.002). Lower doses showed also less severe infections ( 3:10%, 4-6: 37%, 7: 43%; p 0.027) and CMV disease ( 3: 0%, 4-6: 10% , 7: 20%; p 0,008). In contrast, angiographically detected graftvasculopathy was significantly lower in higher ATG groups ( 1.92mg/kg: 48%, 1.92-2.36: 13%, 2.36: 18%, p 0.029). The incidence of cancer was 11% and similar in all ATG groups. Conclusions: In summary, different dosages and durations of ATG induction seems to have an significant impact on the outcome of heart-transplantation. There is a strong need for more studies on optimization of ATG therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
